The novel organoselenium compound 4aa ameliorates osteoporosis by modulating gut microbiota composition and fecal metabolite profiles
4aa prevents estrogen deficiency-induced bone loss by modulating gut microbial composition and function. These findings support the therapeutic of 4aa as a microbiota-targeted therapeutic strategy for osteoporosis management.
Authors
- Yichi Zhang (ORCID: https://orcid.org/0000-0002-2267-5442)
- Shengbin Huang (ORCID: https://orcid.org/0000-0003-4522-2769)
- Mingdong Yi (ORCID: https://orcid.org/0000-0002-9700-3368)
- Xiaoyu Sun (ORCID: https://orcid.org/0000-0001-6779-6005)
- Yousheng Mao (ORCID: https://orcid.org/0000-0003-1120-241X)
- Yao Wu (ORCID: https://orcid.org/0000-0002-0524-4042)
- Shufan Zhao (ORCID: https://orcid.org/0000-0003-2216-4359)
- Jiangping Tu (ORCID: https://orcid.org/0000-0002-7928-1583)
- Yang Chen (ORCID: https://orcid.org/0000-0002-1555-1871)
- Bin Li (ORCID: https://orcid.org/0000-0002-7393-2111)
- Zengqiang Song
- Chaoming Hu
Institutions
- Wenzhou Medical University (CN)
- Stomatology Hospital (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.3389/fendo.2025.1623933
- Primary Topic
- Selenium in Biological Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wenzhou Medical University